Top-News

Elanco Animal Health Aktie News

Aktie
WKN:  A2N6BH ISIN:  US28414H1032 US-Symbol:  ELAN Branche:  Pharmazeutika Land:  USA
21,96 $
-0,03 $
-0,14%
18,852 € 18:53:53 Uhr
Depot/Watchlist
Marktkapitalisierung *
8,97 Mrd. €
Streubesitz
-
KGV
17,81
Index-Zuordnung
-

Elanco Animal Health News

21.11.25 - PR Newswire
Elanco's Credelio™ CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats
Elanco's Credelio™ CAT (lotilaner) Receives First FDA Emergency Use Authorization (EUA) for Treatment of New World Screwworm (NWS) in Cats PR Newswire
20.11.25 - PR Newswire
Elanco to Participate in the Upcoming Investor Conferences
Elanco to Participate in the Upcoming Investor Conferences PR Newswire
13.11.25 - PR Newswire
Alloy Partners Launches OneHealth Studio to Create Startups at the Convergence of Animal, Plant and Human Health
Alloy Partners Launches OneHealth Studio to Create Startups at the Convergence of Animal, Plant and Human Health PR Newswire
05.11.25 - PR Newswire
Elanco Animal Health Reports Third Quarter 2025 Results
Elanco Animal Health Reports Third Quarter 2025 Results PR Newswire
27.10.25 - PR Newswire
Elanco Announces Expansion of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio™ (lotilaner) Labels, Offering Protection Against Lyme Disease and an Emerging Tick Species
Elanco Announces Expansion of Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) and Credelio™ (lotilaner) Labels, Offering Protection Against ...
24.10.25 - PR Newswire
Elanco's Credelio™ (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs
Elanco's Credelio™ (lotilaner) Receives First Ever FDA Emergency Use Authorization (EUA) against New World Screwworm (NWS) in Dogs PR Newswire
16.10.25 - PR Newswire
Elanco to Host Investor Day on December 9
Elanco to Host Investor Day on December 9 PR Newswire
08.10.25 - wallstreetONLINE Redaktion
Noch nicht am Limit: Diese Tiermedizin-Aktie bleibt ein Top-Pick trotz 70 Prozent Kursplus
Trotz eines Kursanstiegs von 70 Prozent in diesem Jahr bleibt Elanco Animal Health laut JPMorgan ein attraktives Investment. Kursziel weiter angehoben.Die Aktie von Elanco ...
01.10.25 - PR Newswire
Elanco Confirms Date and Conference Call for Third Quarter 2025 Financial Results Announcement
Elanco Confirms Date and Conference Call for Third Quarter 2025 Financial Results Announcement PR Newswire
23.09.25 - PR Newswire
Elanco Announces FDA Approves Improved Zenrelia™ (ilunocitinib tablets) Label, Removing Vaccine-Induced Disease Language
Elanco Announces FDA Approves Improved Zenrelia™ (ilunocitinib tablets) Label, Removing Vaccine-​Induced Disease Language PR Newswire
08.09.25 - PR Newswire
Elanco Innovation Builds Momentum, Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Reaches Blockbuster Status
Elanco Innovation Builds Momentum, Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Reaches Blockbuster Status PR Newswire
27.08.25 - PR Newswire
Splenda® Joins Elanco and HATCH to Support 'Nutrition Secure Indianapolis' to Strengthen Family Health Through Nutrition and Education
Splenda® Joins Elanco and HATCH to Support 'Nutrition Secure Indianapolis' to Strengthen Family Health Through Nutrition and Education PR Newswire
26.08.25 - PR Newswire
Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600
Elanco Animal Health Set to Join S&P MidCap 400; Sarepta Therapeutics to Join S&P SmallCap 600 PR Newswire
26.08.25 - PR Newswire
Elanco to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference
Elanco to Participate in Morgan Stanley 23rd Annual Global Healthcare Conference PR Newswire
07.08.25 - PR Newswire
Elanco Animal Health Reports Second Quarter 2025 Results
Elanco Animal Health Reports Second Quarter 2025 Results PR Newswire
24.07.25 - PR Newswire
Elanco Secures Approval of Zenrelia™ (ilunocitinib) in the European Union (EU), Launching Innovative Canine Dermatology Treatment for Itchy Dogs
Elanco Secures Approval of Zenrelia™ (ilunocitinib) in the European Union (EU), Launching Innovative Canine Dermatology Treatment for Itchy Dogs PR Newswire
10.07.25 - PR Newswire
Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement
Elanco Confirms Date and Conference Call for Second Quarter 2025 Financial Results Announcement PR Newswire
09.07.25 - PR Newswire
Elanco Receives USDA Approval for TruCan™ Ultra CIV H3N2/H3N8 (Canine Influenza Vaccine) Bringing to Market a High Standard of Respiratory Protection
Elanco Receives USDA Approval for TruCan™ Ultra CIV H3N2/H3N8 (Canine Influenza Vaccine) Bringing to Market a High Standard of Respiratory Protection PR Newswire
26.06.25 - PR Newswire
Elanco Releases 2024 Impact Report and Introduces New Framework
Elanco Releases 2024 Impact Report and Introduces New Framework PR Newswire
12.06.25 - PR Newswire
Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU's Committee for Veterinary Medicinal Products (CVMP)
Elanco Receives Positive Opinion on Zenrelia (ilunocitinib) from EU's Committee for Veterinary Medicinal Products (CVMP) PR Newswire

Newssuche

Videos

newspaper
10:20 Uhr +2,17%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »